Payment overview · 2025
General Payments
$363.86
17 reported records · 10 companies
Healthcare provider profile · identity verified
Randall Scott, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GREEN COVE SPRINGS, FL · NPI 1619138658
Verified facts
What the public records show
CMS Open Payments records show Randall Scott, D.O. received $363.86 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.59 | 18.9% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $54.48 | 15.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.13 | 13.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.22 | 13.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.76 | 9.6% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $28.66 | 7.9% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $27.28 | 7.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.53 | 6.2% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $14.68 | 4.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.53 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $363.86 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $54.48 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $52.90 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.22 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.22 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.97 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $27.28 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 268 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 212 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 205 | 57 |
| Lisinopril | Lisinopril | 191 | 58 |
| Buprenorphine Hcl | Buprenorphine Hcl | 153 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 27 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 134 | 17 |
| Meloxicam | Meloxicam | 122 | 36 |
| Omeprazole | Omeprazole | 120 | 36 |
| Gabapentin | Gabapentin | 117 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 34 |
| Losartan Potassium | Losartan Potassium | 106 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 101 | 29 |
| Metformin Hcl | Metformin Hcl | 91 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 91 | 30 |
| Azithromycin | Azithromycin | 87 | 58 |
| Montelukast Sodium | Montelukast Sodium | 87 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 30 |
| Sertraline Hcl | Sertraline Hcl | 83 | 24 |
| Mounjaro | Tirzepatide | 77 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 76 | 22 |
| Alprazolam | Alprazolam | 74 | 14 |
| Trazodone Hcl | Trazodone Hcl | 66 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 15 |
| Simvastatin | Simvastatin | 62 | 19 |
| Metformin Hcl Er | Metformin Hcl | 58 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 19 |
| Ezetimibe | Ezetimibe | 54 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 17 |
| Famotidine | Famotidine | 50 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 49 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 16 |
| Furosemide | Furosemide | 48 | 15 |
| Pregabalin | Pregabalin | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 14 |
| Atenolol | Atenolol | 40 | suppressed |
| Prednisone | Prednisone | 39 | 26 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Carvedilol | Carvedilol | 36 | 12 |
| Glipizide | Glipizide | 36 | 14 |
| Tramadol Hcl | Tramadol Hcl | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Eliquis | Apixaban | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | 11 |
| Ondansetron Odt | Ondansetron | 32 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 13 |
| Risperidone | Risperidone | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 11 |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Allopurinol | Allopurinol | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $363.86 · 17 records | ABBVIE INC. | AIRSUPRA, BREZTRI, BRIXADI, MOUNJARO, Natroba, OTEZLA, Omnipod, Ozempic, QULIPTA, REPATHA, SUBLOCADE, Spinosad, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error